Refine
Year of publication
Document Type
- Preprint (611)
- Article (434)
- Conference Proceeding (1)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (1048)
Is part of the Bibliography
- no (1048)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron scattering (experiments) (11)
- Hadron-Hadron Scattering (8)
- Heavy-ion collision (5)
- Collective Flow (4)
- Quark-Gluon Plasma (4)
- Jets (3)
- Jets and Jet Substructure (3)
- (surface) partial differential equations (2)
- 3D spatio-temporal resolved mathematical models (2)
- Atmospheric chemistry (2)
- COVID-19 (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Finite Volumes (2)
- Germany (2)
- Heavy Quark Production (2)
- Immunotherapy (2)
- LHC (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Quarkonium (2)
- acute myeloid leukemia (2)
- computational virology (2)
- immunotherapy (2)
- massively parallel multigrid solvers (2)
- realistic geometries (2)
- viral dynamics (2)
- within-host viral modelling (2)
- 140Ce (1)
- 900 GeV (1)
- ACURATE neo (1)
- AIS (1)
- ALICE (1)
- ALICE detector (1)
- APRI (1)
- ASCT (1)
- Accelerators & Beams (1)
- Acute myeloid leukemia (1)
- Adherens junctions (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Anti-nuclei (1)
- Antibody therapy (1)
- Artificial Intelligence (1)
- Atomic and Molecular Physics (1)
- Atomic, Molecular & Optical (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- Bamlanivimab (1)
- Biodiversity Data (1)
- Biogeochemistry (1)
- Biomarkers (1)
- Biomonitoring (1)
- Bladder cancer (1)
- Blood-brain barrier (1)
- Bloodstream infection (1)
- Bloodstream infections (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Brain tumor (1)
- Burkholderia arboris (1)
- CD36 (1)
- CHIP (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CTLA-4 (1)
- CV9202 (1)
- CVID (1)
- Cancer (1)
- Cancer genomics (1)
- Casirivimab (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Checkpoint inhibitor (1)
- Clinical Trials and Observations (1)
- Clinical trial (1)
- Cluster (1)
- Cohort studies (1)
- Collective Flow, (1)
- Conservation (1)
- Correlative electron and light microscopy (1)
- DBS (1)
- DSS /AOM (1)
- Diagnostic markers (1)
- Digitization (1)
- Electromagnetic transitions (1)
- Electron tomography (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Entomology (1)
- Epidemiology (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus resistance (1)
- Evidence-based guidelines (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extended donor criteria (1)
- FDG-PET/CT (1)
- FIB-4 (1)
- Fibre/foam sandwich radiator (1)
- Freshwater ecology (1)
- GdIr2Si2 (1)
- German PID-NET registry (1)
- Glioma (1)
- Graft function (1)
- Graft survival (1)
- Gram negative bacteria (1)
- HBV (1)
- HDAC-inhibition (1)
- HNSCC (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Head neck cancer (1)
- Heavy Ion Experiment (1)
- Hematology (1)
- Hematopoietic stem cell transplantation (1)
- Herbaria (1)
- Hypofractionated radiotherapy (1)
- ICU (1)
- IL -17 (1)
- IL -23 (1)
- IL 23p19 knockout mouse (1)
- ISS (1)
- IgG substitution therapy (1)
- Imdevimab (1)
- Immunomonitoring (1)
- Incidence (1)
- Induction therapy (1)
- Intensive care units (1)
- Invariant Mass Distribution (1)
- Invasive species (1)
- Ionisation energy loss (1)
- Isoflurane (1)
- Jet Physics (1)
- Jet Substructure (1)
- Lesion (1)
- Liver transplantation (1)
- Locally advanced (1)
- Long term output (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MACS (1)
- MRI (1)
- Magnetic resonance imaging (MRI) (1)
- Marginal grafts (1)
- Material budget (1)
- Mechanisms of disease (1)
- Minimum Bias (1)
- Models & methods for nuclear reactions (1)
- Molecular diagnostic testing (1)
- Molecular matched therapy (1)
- Molecular medicine (1)
- Molecular profiling (1)
- Monte Carlo (1)
- Mott transition (1)
- Multi-Parton Interactions (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Multivariate analysis (1)
- Myeloid Neoplasia (1)
- NMR spectroscopy (1)
- NSCLC (1)
- Neural network (1)
- Neutron physics (1)
- Neutropenia (1)
- Nivolumab (1)
- Nuclear reactions (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoporosis (1)
- P2X7 receptor (1)
- PD-1 (1)
- PD-1 inhibitor (1)
- PDEs (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb collisions (1)
- Phylogenomics (1)
- Pneumonia (1)
- Poecilia mexicana (1)
- Polarization (1)
- Population genetics (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Psoriasis vulgaris (1)
- QCD (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- RNA (1)
- RNA decay (1)
- Radiation detectors (1)
- Radiative capture (1)
- Radical cystectomy (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Registries (1)
- Relativistic heavy-ion collisions (1)
- Renal cell carcinoma (1)
- Research Infrastructure (1)
- Resolution Parameter (1)
- Resonance reactions (1)
- SMAD (1)
- Semantics (1)
- Sexual selection (1)
- Status epilepticus (1)
- Stenotrophomonas maltophilia (1)
- Stentoplasty (1)
- Systematic Uncertainty (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- TAVR (1)
- TGFβ (1)
- TR (1)
- Tacrolimus (1)
- Targeted therapy (1)
- Taxonomy (1)
- Thermodynamics (1)
- Thoracic trauma (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Time Projection Chamber (1)
- TmRh2Si2 (1)
- Tracking (1)
- Transition radiation detector (1)
- Transitional cell carcinoma (1)
- Transverse momentum (1)
- Treatment (1)
- Trigger (1)
- Tumor growth (1)
- Urothelial cancer (1)
- VIM (1)
- Vector Boson Production (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Viral load (1)
- X-ray crystallography (1)
- X-ray irradiation (1)
- Xenon-based gas mixture (1)
- acoustic radiation force impulse imaging (1)
- adaptation (1)
- advanced melanoma (1)
- adversity (1)
- age (1)
- allostasis (1)
- anti-epileptic drug (1)
- aortic stenosis (1)
- autologous stem cell transplantation (1)
- biomarker (1)
- blood cell mutations (1)
- brain metastases (1)
- brain metastasis (1)
- brain shift (1)
- burkholderia (1)
- burkholderia cepacia complex infections (1)
- calcium dynamics (1)
- calcium-independent phospholipase A2β (1)
- capture (1)
- cdk2/cyclin A (1)
- cerebral pseudoprogression (1)
- cerium (1)
- chemoconvulsant (1)
- chemotherapy (1)
- chronic colitis (1)
- clonal dominance (1)
- clonal haematopoiesis (1)
- clonal hematopoiesis (1)
- clonal transfer (1)
- colon cancer (1)
- community assembly (1)
- complete response (1)
- complex systems (1)
- coping (1)
- correlated electrons (1)
- cross-section (1)
- cytarabine dose (1)
- dE/dx (1)
- detailed modeling (1)
- detector (1)
- diffuse large B cell lymphoma (1)
- discontinuation (1)
- discontinuous dose dependency (1)
- disease outbreaks (1)
- disease progression (1)
- disorder (1)
- distributed computation (1)
- dynamic system (1)
- ectosomes (1)
- elderly (1)
- electrical stimulation (1)
- electrophoresis (1)
- epileptogenesis (1)
- essential tremor (1)
- everolimus (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- familial amyloid nephropathy with urticaria and deafness (1)
- female choice (1)
- fibrotest (1)
- flux growth (1)
- gel (1)
- gene expression profiling (1)
- gene signature (1)
- generalized additive model (1)
- genome (1)
- glioblastoma (1)
- guidelines (1)
- head and neck squamous cell carcinoma (1)
- healthcare systems (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatitis C virus (1)
- hepatitis C virus (HCV) (1)
- hippocampal sclerosis (1)
- homeostasis (1)
- host response (1)
- hybrid (1)
- hypoxia (1)
- immune checkpoint blockade (1)
- immune checkpoint inhibitors (1)
- immune checkpoint inhibitors (ICI) (1)
- immune modulation (1)
- immune related adverse events (irAE) (1)
- infections (1)
- inflammasome (1)
- inflammation (1)
- information storage (1)
- inpatient hospital admissions (1)
- interleukin-1β (1)
- leukemia (1)
- liver metastasis (1)
- local information dynamics (1)
- lockdown (1)
- loss-of-function (1)
- low-dose radiation therapy (1)
- lung cancer (1)
- mRNA active cancer immunotherapy (1)
- magnetism (1)
- mathematical models of viral RNA cycle (1)
- medical device (1)
- medical informatics initiative (1)
- mental health (1)
- metastatic renal cell carcinoma (1)
- microbial colonization (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- mouthwash (1)
- mouthwash solution (1)
- n_TOF (1)
- neoadjuvant immunochemotherapy (1)
- neural dynamics (1)
- neurological complication (1)
- neurological side effects (1)
- neuron (1)
- neutron (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- non-independent mate choice (1)
- non-invasive fibrosis assessment (1)
- noncoding RNA (1)
- ntracellular signaling (1)
- nucleosynthesis (1)
- organic conductor (1)
- outbreak (1)
- p+p collisions (1)
- p47phox (1)
- pandemic (1)
- parallel (1)
- parameter estimation (1)
- patterns of progression (1)
- pembrolizumab (1)
- perioperative ischemia (1)
- phase IV (1)
- point shear wave elastography (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- predator recognition (1)
- predictive coding (1)
- pressure (1)
- primary immunodeficiency (PID) (1)
- propensity score matching (1)
- pulsed-field (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- reproducibility (1)
- rigor (1)
- risk stratification (1)
- s-process (1)
- second-line (1)
- second-line immunotherapy (1)
- soil bacteria communities (1)
- somatic mutations (1)
- spatio-temporal analysis (1)
- standardization (1)
- status epilepticus (1)
- stereotactic radiosurgery (1)
- stress (1)
- survival (1)
- targeted therapy (1)
- temporal lobe epilepsy (1)
- transcatheter aortic valve replacement (1)
- transfemoral (1)
- transient elastography (1)
- treatment resistance (1)
- tumor microenvironment (1)
- university hospitals (1)
- uveal melanoma (1)
- variable selection (1)
- ventralis intermedius nucleus (1)
- visual system (1)
- voltage sensitive dye imaging (1)
Institute
- Physik (955)
- Frankfurt Institute for Advanced Studies (FIAS) (852)
- Informatik (822)
- Medizin (66)
- Geowissenschaften (9)
- Biowissenschaften (5)
- ELEMENTS (3)
- Informatik und Mathematik (3)
- Institut für Ökologie, Evolution und Diversität (3)
- Biochemie und Chemie (2)
Aims: Somatic mutations in haematopoietic stem cells can lead to the clonal expansion of mutated blood cells, known as clonal haematopoiesis (CH). Mutations in the most prevalent driver genes DNMT3A and TET2 with a variant allele frequency (VAF) ≥ 2% have been associated with atherosclerosis and chronic heart failure of ischemic origin (CHF). However, the effects of mutations in other driver genes for CH with low VAF (<2%) on CHF are still unknown.
Methods and results: Therefore, we analysed mononuclear bone marrow and blood cells from 399 CHF patients by deep error-corrected targeted sequencing of 56 genes and associated mutations with the long-term mortality in these patients (3.95 years median follow-up). We detected 1113 mutations with a VAF ≥ 0.5% in 347 of 399 patients, and only 13% had no detectable CH. Despite a high prevalence of mutations in the most frequently mutated genes DNMT3A (165 patients) and TET2 (107 patients), mutations in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2 were associated with increased death compared with the average death rate of all patients. To avoid confounding effects, we excluded patients with DNMT3A-related, TET2-related, and other clonal haematopoiesis of indeterminate potential (CHIP)-related mutations with a VAF ≥ 2% for further analyses. Kaplan–Meier survival analyses revealed a significantly higher mortality in patients with mutations in either of the seven genes (53 patients), combined as the CH-risk gene set for CHF. Baseline patient characteristics showed no significant differences in any parameter including patient age, confounding diseases, severity of CHF, or blood cell parameters except for a reduced number of platelets in patients with mutations in the risk gene set in comparison with patients without. However, carrying a mutation in any of the risk genes remained significant after multivariate cox regression analysis (hazard ratio, 3.1; 95% confidence interval, 1.8–5.4; P < 0.001), whereas platelet numbers did not.
Conclusions: Somatic mutations with low VAF in a distinct set of genes, namely, in CBL, CEBPA, EZH2, GNB1, PHF6, SMC1A, and SRSF2, are significantly associated with mortality in CHF, independently of the most prevalent CHIP-mutations in DNMT3A and TET2. Mutations in these genes are prevalent in young CHF patients and comprise an independent risk factor for the outcome of CHF, potentially providing a novel tool for risk assessment in CHF.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Background: Fumaric acid esters (FAEs; Fumaderm®) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi®) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. Objectives: To compare risankizumab treatment to FAEs in patients with psoriasis. Methods: This phase III randomized, active-controlled, open-label study with blinded assessment of efficacy was conducted in Germany. Patients were randomized (1 : 1) to subcutaneous risankizumab 150 mg (weeks 0, 4 and 16) or oral FAEs at increasing doses from 30 mg daily (week 0) up to 720 mg daily (weeks 8–24). Enrolled patients were adults naïve to and candidates for systemic therapy, with chronic moderate-to-severe plaque psoriasis. Phototherapy was not allowed within 14 days before or during the study. Results: Key efficacy endpoints were met at week 24 for risankizumab (n = 60) vs. FAEs (n = 60) (P < 0·001): achievement of a ≥ 90% improvement in Psoriasis Area and Severity Index (PASI; primary endpoint 83·3% vs. 10·0%), ≥ 100% improvement in PASI (50·0% vs. 5·0%), ≥ 75% improvement in PASI (98·3% vs. 33·3%), ≥ 50% improvement in PASI (100% vs. 53·3%) and a Static Physician’s Global Assessment of clear/almost clear (93·3% vs. 38·3%). The rates of gastrointestinal disorders, flushing, lymphopenia and headache were higher in the FAE group. One patient receiving risankizumab reported a serious infection (influenza, which required hospitalization). There were no malignancies, tuberculosis or opportunistic infections in either treatment arm. Conclusions: Risankizumab was found to be superior to FAEs, providing earlier and greater improvement in psoriasis outcomes that persisted with continued treatment, and more favourable safety results, which is consistent with the known safety profile. No new safety signals for risankizumab or FAEs were observed.
There is a need for diagnostic biomarkers of epilepsy and status epilepticus to support clinical examination, electroencephalography and neuroimaging. Extracellular microRNAs may be potentially ideal biomarkers since some are expressed uniquely within specific brain regions and cell types. Cerebrospinal fluid offers a source of microRNA biomarkers with the advantage of being in close contact with the target tissue and sites of pathology. Here we profiled microRNA levels in cerebrospinal fluid from patients with temporal lobe epilepsy or status epilepticus, and compared findings to matched controls. Differential expression of 20 microRNAs was detected between patient groups and controls. A validation phase included an expanded cohort and samples from patients with other neurological diseases. This identified lower levels of miR-19b in temporal lobe epilepsy compared to controls, status epilepticus and other neurological diseases. Levels of miR-451a were higher in status epilepticus compared to other groups whereas miR-21-5p differed in status epilepticus compared to temporal lobe epilepsy but not to other neurological diseases. Targets of these microRNAs include proteins regulating neuronal death, tissue remodelling, gliosis and inflammation. The present study indicates cerebrospinal fluid contains microRNAs that can support differential diagnosis of temporal lobe epilepsy and status epilepticus from other neurological and non-neurological diseases.
Effects of BPA in snails
(2006)
It is an ethical requirement that new findings be presented in light of and in conjunction with a balanced evaluation of the current knowledge and published literature. We believe that Oehlmann et al. (2006) violated this general principle in several ways. For example, the authors inferred that prosobranch snails have a functional estrogen receptor and therefore a much higher sensitivity to estrogens and endocrine-disrupting compounds (EDCs) than other species previously reported in the literature. We found several other problems in their article...
Background: The inclusion of immune checkpoint inhibitors (ICIs) in therapeutic algorithms has led to significant survival benefits in patients with various metastatic cancers. Concurrently, an increasing number of neurological immune related adverse events (IRAE) has been observed. In this retrospective analysis, we examine the ICI-induced incidence of cerebral pseudoprogression and propose a classification system.
Methods: We screened our hospital information system to identify patients with any in-house ICI treatment for any tumor disease during the years 2007-2019. All patients with cerebral MR imaging (cMRI) of sufficient diagnostic quality were included. cMRIs were retrospectively analyzed according to immunotherapy response assessment for neuro-oncology (iRANO) criteria.
Results: We identified 12 cases of cerebral pseudoprogression in 123 patients treated with ICIs and sufficient MRI. These patients were receiving ICI therapy for lung cancer (n=5), malignant melanoma (n=4), glioblastoma (n=1), hepatocellular carcinoma (n=1) or lymphoma (n=1) when cerebral pseudoprogression was detected. Median time from the start of ICI treatment to pseudoprogression was 5 months. All but one patient developed neurological symptoms. Three different patterns of cerebral pseudoprogression could be distinguished: new or increasing contrast-enhancing lesions, new or increasing T2 predominant lesions and cerebral vasculitis type pattern.
Conclusion: Cerebral pseudoprogression followed three distinct patterns and was detectable in 3.2% of all patients during ICI treatment and in 9.75% of the patients with sufficient brain imaging follow up. The fact that all but one of the affected patients developed neurological symptoms, which would be classified as progressive disease according to iRANO criteria, mandates vigilance in the diagnosis and treatment of ICI-induced cerebral lesions.
Background: Epileptic seizures are common clinical features in patients with acute subdural hematoma (aSDH); however, diagnostic feasibility and therapeutic monitoring remain limited. Surface electroencephalography (EEG) is the major diagnostic tool for the detection of seizures but it might be not sensitive enough to detect all subclinical or nonconvulsive seizures or status epilepticus. Therefore, we have planned a clinical trial to evaluate a novel treatment modality by perioperatively implanting subdural EEG electrodes to diagnose seizures; we will then treat the seizures under therapeutic monitoring and analyze the clinical benefit.
Methods: In a prospective nonrandomized trial, we aim to include 110 patients with aSDH. Only patients undergoing surgical removal of aSDH will be included; one arm will be treated according to the guidelines of the Brain Trauma Foundation, while the other arm will additionally receive a subdural grid electrode. The study's primary outcome is the comparison of incidence of seizures and time-to-seizure between the interventional and control arms. Invasive therapeutic monitoring will guide treatment with antiseizure drugs (ASDs). The secondary outcome will be the functional outcome for both groups as assessed via the Glasgow Outcome Scale and modified Rankin Scale both at discharge and during 6 months of follow-up. The tertiary outcome will be the evaluation of chronic epilepsy within 2-4 years of follow-up.
Discussion: The implantation of a subdural EEG grid electrode in patients with aSDH is expected to be effective in diagnosing seizures in a timely manner, facilitating treatment with ASDs and monitoring of treatment success. Moreover, the occurrence of epileptiform discharges prior to the manifestation of seizure patterns could be evaluated in order to identify high-risk patients who might benefit from prophylactic treatment with ASDs.
Trial registration: ClinicalTrials.gov identifier no. NCT04211233.
Background: In September 2018, Burkholderia cepacia complex (BCC) infections in 3 patients associated with exposure to a mouthwash solution (MWS) were reported to the Robert Koch Institute (RKI). As the product was still on the market and the scale of the outbreak was unclear, a nation-wide investigation was initiated.
Methods: We aimed to investigate BCC infections/colonizations associated with MWS. Hospitals, laboratories, and public health services were informed that BCC isolates should be sent to the RKI. These isolates were typed by pulsed-field gel electrophoresis (PFGE) and whole-genome sequencing (WGS) including development of an ad hoc core genome MLST (cgMLST) scheme.
Results: In total, 36 patients from 6 hospitals met the case definition, the last patient in November 2018. Twenty-nine isolates from 26 of these patients were available for typing. WGS analysis revealed 2 distinct cgMLST clusters. Cluster 1 (Burkholderia arboris) contained isolates from patients and MWS obtained from 4 hospitals and isolates provided by the manufacturer. Patient and MWS isolates from another hospital were assigned to cluster 2 (B. cepacia).
Conclusions: The combined clinical, epidemiological, and microbiological investigation, including whole-genome analysis, allowed for uncovering a supraregional BCC outbreak in health care settings. Strains of B. arboris and B. cepacia were identified as contaminating species of MWS bottles and subsequent colonization and putative infection of patients in several hospitals. Despite a recall of the product by the manufacturer in August 2018, the outbreak lasted until December 2018. Reporting of contaminated medical products and recalls should be optimized to protect patients.
The radiative electron capture (REC) into the K shell of bare Xe ions colliding with a hydrogen gas target has been investigated. In this study, the degree of linear polarization of the K-REC radiation was measured and compared with rigorous relativistic calculations as well as with the previous results recorded for U92+. Owing to the improved detector technology, a significant gain in precision of the present polarization measurement is achieved compared to the previously published results. The obtained data confirms that for medium-Z ions such as Xe, the REC process is a source of highly polarized x rays which can easily be tuned with respect to the degree of linear polarization and the photon energy. We argue, in particular, that for relatively low energies the photons emitted under large angles are almost fully linear polarized.
Resilience has been defined as the maintenance or quick recovery of mental health during and after times of adversity. How to operationalize resilience and to determine the factors and processes that lead to good long-term mental health outcomes in stressor-exposed individuals is a matter of ongoing debate and of critical importance for the advancement of the field. One of the biggest challenges for implementing an outcome-based definition of resilience in longitudinal observational study designs lies in the fact that real-life adversity is usually unpredictable and that its substantial qualitative as well as temporal variability between subjects often precludes defining circumscribed time windows of inter-individually comparable stressor exposure relative to which the maintenance or recovery of mental health can be determined. To address this pertinent issue, we propose to frequently and regularly monitor stressor exposure (E) and mental health problems (P) throughout a study's observation period [Frequent Stressor and Mental Health Monitoring (FRESHMO)-paradigm]. On this basis, a subject's deviation at any single monitoring time point from the study sample's normative E–P relationship (the regression residual) can be used to calculate that subject's current mental health reactivity to stressor exposure (“stressor reactivity,” SR). The SR score takes into account the individual extent of experienced adversity and is comparable between and within subjects. Individual SR time courses across monitoring time points reflect intra-individual temporal variability in SR, where periods of under-reactivity (negative SR score) are associated with accumulation of fewer mental health problems than is normal for the sample. If FRESHMO is accompanied by regular measurement of potential resilience factors, temporal changes in resilience factors can be used to predict SR time courses. An increase in a resilience factor measurement explaining a lagged decrease in SR can then be considered to index a process of adaptation to stressor exposure that promotes a resilient outcome (an allostatic resilience process). This design principle allows resilience research to move beyond merely determining baseline predictors of resilience outcomes, which cannot inform about how individuals successfully adjust and adapt when confronted with adversity. Hence, FRESHMO plus regular resilience factor monitoring incorporates a dynamic-systems perspective into resilience research.
A central motivation for the development of x-ray free-electron lasers has been the prospect of time-resolved single-molecule imaging with atomic resolution. Here, we show that x-ray photoelectron diffraction—where a photoelectron emitted after x-ray absorption illuminates the molecular structure from within—can be used to image the increase of the internuclear distance during the x-ray-induced fragmentation of an O2 molecule. By measuring the molecular-frame photoelectron emission patterns for a two-photon sequential K-shell ionization in coincidence with the fragment ions, and by sorting the data as a function of the measured kinetic energy release, we can resolve the elongation of the molecular bond by approximately 1.2 a.u. within the duration of the x-ray pulse. The experiment paves the road toward time-resolved pump-probe photoelectron diffraction imaging at high-repetition-rate x-ray free-electron lasers.
Aim: In the CheckRad-CD8 trial patients with locally advanced head and neck squamous cell cancer are treated with a single cycle of induction chemo-immunotherapy (ICIT). Patients with pathological complete response (pCR) in the re-biopsy enter radioimmunotherapy. Our goal was to study the value of F-18-FDG PET/CT in the prediction of pCR after induction therapy.
Methods: Patients treated within the CheckRad-CD8 trial that additionally received FDG- PET/CT imaging at the following two time points were included: 3–14 days before (pre-ICIT) and 21–28 days after (post-ICIT) receiving ICIT. Tracer uptake in primary tumors (PT) and suspicious cervical lymph nodes (LN +) was measured using different quantitative parameters on EANM Research Ltd (EARL) accredited PET reconstructions. In addition, mean FDG uptake levels in lymphatic and hematopoietic organs were examined. Percent decrease (Δ) in FDG uptake was calculated for all parameters. Biopsy of the PT post-ICIT acquired after FDG-PET/CT served as reference. The cohort was divided in patients with pCR and residual tumor (ReTu).
Results: Thirty-one patients were included. In ROC analysis, ΔSUVmax PT performed best (AUC = 0.89) in predicting pCR (n = 17), with a decline of at least 60% (sensitivity, 0.77; specificity, 0.93). Residual SUVmax PT post-ICIT performed best in predicting ReTu (n = 14), at a cutpoint of 6.0 (AUC = 0.91; sensitivity, 0.86; specificity, 0.88). Combining two quantitative parameters (ΔSUVmax ≥ 50% and SUVmax PT post-ICIT ≤ 6.0) conferred a sensitivity of 0.81 and a specificity of 0.93 for determining pCR. Background activity in lymphatic organs or uptake in suspected cervical lymph node metastases lacked significant predictive value.
Conclusion: FDG-PET/CT can identify patients with pCR after ICIT via residual FDG uptake levels in primary tumors and the related changes compared to baseline. FDG-uptake in LN + had no predictive value.
Trial registry: ClinicalTrials.gov identifier: NCT03426657.
Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the International Cancer Genome Consortium (ICGC), we performed whole genome and transcriptome sequencing of 39 sporadic BL. Here, we unravel interaction of structural, mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation together with the pathognomonic IG-MYC translocation. Moreover, by mapping IGH translocation breakpoints, we provide evidence that the precursor of at least a subset of BL is a B-cell poised to express IGHA. We describe the landscape of mutations, structural variants, and mutational processes, and identified a series of driver genes in the pathogenesis of BL, which can be targeted by various mechanisms, including IG-non MYC translocations, germline and somatic mutations, fusion transcripts, and alternative splicing.
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral therapy indication. The aim of this study was to prospectively assess the utility of point shear wave elastography (pSWE) for longitudinal non-invasive fibrosis assessment in a large cohort of untreated patients with chronic HBeAg-negative hepatitis B virus (HBV) infection.
Methods: 407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years. Patients were classified into one of the three groups: inactive carriers (IC; HBV-DNA <2000 IU/mL and ALT <40 U/L); grey zone group 1 (GZ-1; HBV DNA <2000 IU/mL and ALT >40 U/L); grey zone group 2 (GZ-2; HBV-DNA >2000 IU/mL and ALT <40 U/L).
Results: pSWE results were significantly correlated with TE (r = 0.29, p < 0.001) and APRI (r = 0.17; p = 0.005). Median pSWE values did not differ between IC, GZ-1 and GZ-2 patients (p = 0.82, p = 0.17, p = 0.34). During six years of follow-up, median pSWE and TE values did not differ significantly over time (TE: p = 0.27; pSWE: p = 0.05).
Conclusion: Our data indicate that pSWE could be useful for non-invasive fibrosis assessment and follow-up in patients with HBeAg-negative chronic HBV infection.
Background: Hypoxia is a key driver for infiltrative growth in experimental gliomas. It has remained elusive whether tumor hypoxia in glioblastoma patients contributes to distant or diffuse recurrences. We therefore investigated the influence of perioperative cerebral ischemia on patterns of progression in glioblastoma patients.
Methods: We retrospectively screened MRI scans of 245 patients with newly diagnosed glioblastoma undergoing resection for perioperative ischemia near the resection cavity. 46 showed relevant ischemia nearby the resection cavity. A control cohort without perioperative ischemia was generated by a 1:1 matching using an algorithm based on gender, age and adjuvant treatment. Both cohorts were analyzed for patterns of progression by a blinded neuroradiologist.
Results: The percentage of diffuse or distant recurrences at first relapse was significantly higher in the cohort with perioperative ischemia (61.1%) compared to the control cohort (19.4%). The results of the control cohort matched well with historical data. The change in patterns of progression was not associated with a difference in survival.
Conclusions: This study reveals an unrecognized association of perioperative cerebral ischemia with distant or diffuse recurrence in glioblastoma. It is the first clinical study supporting the concept that hypoxia is a key driver of infiltrative tumor growth in glioblastoma patients.
Radiographic and safety details of vertebral body stenting : results from a multicenter chart review
(2013)
Background: Up to one third of BKP treated cases shows no appreciable height restoration due to loss of both restored height and kyphotic realignment after balloon deflation. This shortcoming has called for an improved method that maintains the height and realignment reached by the fully inflated balloon until stabilization of the vertebral body by PMMA-based cementation. Restoration of the physiological vertebral body height for pain relief and for preventing further fractures of adjacent and distant vertebral bodies must be the main aim for such a method. A new vertebral body stenting system (VBS) stabilizes the vertebral body after balloon deflation until cementation. The radiographic and safety results of the first 100 cases where VBS was applied are presented.
Methods: During the planning phase of an ongoing international multicenter RCT, radiographic, procedural and followup details were retrospectively transcribed from charts and xrays for developing and testing the case report forms. Radiographs were centrally assessed at the institution of the first/senior author.
Results: 100 patients (62 with osteoporosis) with a total of 103 fractured vertebral bodies were treated with the VBS system. 49 were females with a mean age of 73.2 years; males were 66.7 years old. The mean preoperative anterior-middle-posterior heights were 20.3-17.6-28.0 mm, respectively. The mean local kyphotic angle was 13.1°. The mean preoperative Beck Index (anterior edge height/posterior edge height) was 0.73, the mean alternative Beck Index (middle height/posterior edge height) was 0.63. The mean postoperative heights were restored to 24.5-24.6-30.4 mm, respectively. The mean local kyphotic angle was reduced to 8.9°. The mean postoperative Beck Index was 0.81, the mean alternative one was 0.82. The overall extrusion rate was 29.1%, the symptomatic one was 1%. In the osteoporosis subgroup there were 23.8% extrusions. Within the three months followup interval there were 9% of adjacent and 4% of remote new fractures, all in the osteoporotic group.
Conclusions: VBS showed its strengths especially in realignment of crush and biconcave fractures. Given that fracture mobility is present, the realignment potential is sound and increases with the severity of preoperative vertebral body deformation.
Background: Clock genes and their protein products regulate circadian rhythms in mammals but have also been implicated in various physiological processes, including bone formation. Osteoblasts build new mineralized bone whereas osteoclasts degrade it thereby balancing bone formation. To evaluate the contribution of clock components in this process, we investigated mice mutant in clock genes for a bone volume phenotype. Methodology/Principal Findings: We found that Per2Brdm1 mutant mice as well as mice lacking Cry2-/- displayed significantly increased bone volume at 12 weeks of age, when bone turnover is high. Per2Brdm1 mutant mice showed alterations in parameters specific for osteoblasts whereas mice lacking Cry2-/- displayed changes in osteoclast specific parameters. Interestingly, inactivation of both Per2 and Cry2 genes leads to normal bone volume as observed in wild type animals. Importantly, osteoclast parameters affected due to the lack of Cry2, remained at the level seen in the Cry2-/- mutants despite the simultaneous inactivation of Per2. Conclusions/Significance: This indicates that Cry2 and Per2 affect distinct pathways in the regulation of bone volume with Cry2 influencing mostly the osteoclastic cellular component of bone and Per2 acting on osteoblast parameters.